Effect of Androgel [testosterone] on total and regional adipose tissue and lean body mass in type 2 diabetic patients with hypogonadism.

Trial Profile

Effect of Androgel [testosterone] on total and regional adipose tissue and lean body mass in type 2 diabetic patients with hypogonadism.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2015

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Jun 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 20 Apr 2010 Trial sponsor changed from Solvay Pharmaceuticals to abbott lab as reported by ClinicalTrials.gov.
    • 27 Jan 2009 Planned end date changed from 1 Jul 2009 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top